A detailed history of Prelude Capital Management, LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 12,519 shares of ARCT stock, worth $193,794. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,519
Previous 12,519 -0.0%
Holding current value
$193,794
Previous $290,000 -0.0%
% of portfolio
0.02%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.08 - $25.38 $9,636 - $13,527
533 Added 4.45%
12,519 $290,000
Q2 2024

Aug 14, 2024

BUY
$24.35 - $44.39 $291,859 - $532,058
11,986 New
11,986 $291,000
Q4 2023

Feb 14, 2024

BUY
$17.71 - $32.97 $15,885 - $29,574
897 Added 10.6%
9,359 $295,000
Q3 2023

Nov 14, 2023

SELL
$25.44 - $37.35 $9,260 - $13,595
-364 Reduced 4.12%
8,462 $216,000
Q2 2023

Aug 14, 2023

SELL
$23.94 - $32.36 $90,205 - $121,932
-3,768 Reduced 29.92%
8,826 $253,000
Q1 2023

May 15, 2023

BUY
$14.72 - $23.97 $185,383 - $301,878
12,594 New
12,594 $301,000
Q2 2022

Aug 15, 2022

BUY
$12.26 - $31.17 $73,878 - $187,830
6,026 Added 105.22%
11,753 $185,000
Q3 2020

Nov 16, 2020

SELL
$37.49 - $63.19 $77,716 - $130,992
-2,073 Reduced 26.58%
5,727 $246,000
Q2 2020

Aug 14, 2020

SELL
$12.66 - $58.27 $298,003 - $1.37 Million
-23,539 Reduced 75.11%
7,800 $365,000
Q1 2020

May 15, 2020

BUY
$9.31 - $18.26 $4,450 - $8,728
478 Added 1.55%
31,339 $426,000
Q4 2019

Feb 14, 2020

BUY
$8.93 - $12.41 $73,502 - $102,146
8,231 Added 36.37%
30,861 $335,000
Q3 2019

Nov 14, 2019

BUY
$8.8 - $14.5 $44,994 - $74,138
5,113 Added 29.19%
22,630 $232,000
Q2 2019

Aug 14, 2019

BUY
$5.78 - $9.79 $101,248 - $171,491
17,517 New
17,517 $165,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $411M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.